Guggenheim Securities Initiates ANI Pharma With Buy

Guggenheim Securities initiated coverage on ANI Pharma

with a Buy rating. The target price for ANI Pharma is set to $65. ANI Pharma shares have gained 259.71% over the past 52 weeks, while the S&P 500 index has surged 12.08% in the same period. ANI Pharma shares rose 4.49% to close at $54.28 on Friday.